Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer
Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer
The treating physician/investigator contacts Lilly when, based on their medical opinion, a
 patient meets the criteria for inclusion in the expanded access program.
Inclusion Criteria:

 -  Patients with hormone receptor positive metastatic breast cancer for whom there is
 reasonable expectation that abemaciclib may provide clinical benefit and who are
 suitable to receive abemaciclib.